Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging (DOSI)

The prospective multi-center ACRIN 6691 trial was designed to evaluate whether changes from baseline to mid-therapy in a Diffuse Optical Spectroscopic Imaging (DOSI)-derived imaging endpoint, the Tissue Optical Index (TOI), predict pathologic complete response (pCR) in women undergoing breast cancer...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Res
Prif Awduron: Tromberg, Bruce J., Zhang, Zheng, Leproux, Anaïs, O’Sullivan, Thomas D., Cerussi, Albert E., Carpenter, Philip, Mehta, Rita S., Roblyer, Darren, Yang, Wei, Paulsen, Keith D., Pogue, Brian W., Jiang, Shudong, Kaufman, Peter, Yodh AG, Arjun G., Chung, So Hyun, Schnall, Mitchell, Snyder, Bradley S., Hylton, Nola, Boas, David A., Carp, Stefan A., Isakoff, Steven J., Mankoff, David
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2016
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5148152/
https://ncbi.nlm.nih.gov/pubmed/27527559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-0346
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg